ストックスクリーナーアプリを入手
10.99
1.08%
-0.12
前日終値:
$11.11
開ける：
$11.1
24時間の取引高:
2.30M
Relative Volume:
0.31
時価総額：
$922.56M
収益：
-
当期純損益:
$-314.85M
株価収益率:
-3.0677
EPS:
-3.5825
ネットキャッシュフロー:
$-283.27M
1週間 パフォーマンス:
-5.09%
1か月 パフォーマンス:
+29.75%
6か月 パフォーマンス:
+36.86%
1年 パフォーマンス:
+2.04%
1日の値動き範囲:
$10.46
$11.11
1週間の範囲:
$10.46
$11.85
52週間の値動き範囲:
$1.50
$13.24
Replimune Group Inc Stock (REPL) Company Profile
Compare REPL vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
10.99 | 922.56M | 0 | -314.85M | -283.27M | -3.5825 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-13 | ダウングレード | BMO Capital Markets | Market Perform → Underperform |
| 2026-04-13 | ダウングレード | H.C. Wainwright | Buy → Sell |
| 2026-04-13 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2026-04-13 | ダウングレード | Jefferies | Buy → Hold |
| 2026-04-13 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2026-04-13 | ダウングレード | Wedbush | Outperform → Neutral |
| 2026-04-10 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2025-11-03 | アップグレード | BMO Capital Markets | Underperform → Market Perform |
| 2025-10-27 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2025-10-20 | アップグレード | JP Morgan | Underweight → Neutral |
| 2025-10-20 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2025-10-20 | アップグレード | Wedbush | Neutral → Outperform |
| 2025-09-19 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2025-07-30 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2025-07-23 | ダウングレード | BMO Capital Markets | Outperform → Underperform |
| 2025-07-23 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2025-07-23 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-07-22 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2025-07-22 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-07-22 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2025-07-22 | ダウングレード | Wedbush | Outperform → Neutral |
| 2025-06-20 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-08-28 | 開始されました | ROTH MKM | Buy |
| 2023-04-17 | 再開されました | Piper Sandler | Overweight |
| 2021-11-19 | 開始されました | Piper Sandler | Overweight |
| 2021-10-15 | 再開されました | BTIG Research | Buy |
| 2020-11-17 | 開始されました | BTIG Research | Buy |
| 2020-11-02 | 開始されました | Jefferies | Buy |
| 2020-10-15 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-07-01 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2020-05-05 | 開始されました | Barclays | Overweight |
| 2019-09-04 | 開始されました | ROTH Capital | Buy |
| 2019-07-23 | 開始されました | Chardan Capital Markets | Buy |
| 2019-07-12 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-07-08 | 開始されました | H.C. Wainwright | Buy |
| 2019-04-25 | 開始されました | Wedbush | Outperform |
| 2019-01-23 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-08-14 | 開始されました | JP Morgan | Overweight |
| 2018-08-14 | 開始されました | Leerink Partners | Outperform |
すべてを表示
Replimune Group Inc (REPL) 最新ニュース
Replimune soars after FDA reconsiders denial of cancer drug - MSN
REPL Vs IOVA: FDA Decision Day Could Test Biotech Bulls’ Conviction On These Melanoma Plays - Stocktwits
Replimune Group Inc. (REPL) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
REPL Stock On Track To Hit All-Time Lows – Here’s Why This Analyst Slashed Price Target By 85% - Stocktwits
9 Health Care Stocks With Whale Alerts In Today’s Session - Benzinga
REPL Stock Rallies In Anticipation Of FDA Decision On Skin Cancer Drug - Stocktwits
REPL Stock Lost 19% Of Its Value Today – Why Did The FDA Refuse Approval For Its Experimental Melanoma Drug? - Stocktwits
REPL Stock On Track For Worst Drop In Nearly 7 Months Ahead Of FDA Decision On Skin Cancer Drug - Stocktwits
Replimune Group stock and its cancer immunotherapy pipeline - Ad-hoc-news.de
3 Biotech Stocks to Watch Before Wall Street Catches On - TradingView
The week in pharma: action, reaction and insight – week to July 3, 2026 - The Pharma Letter
Replimune says FDA rejected its lead drug for skin cancer - MSN
Analysts Offer Insights on Healthcare Companies: Replimune Group (REPL) and Roche Holding AG (OtherRHHVF) - The Globe and Mail
REPL Maintains Neutral Rating by Wedbush -- Price Target Raised to $9.00 - GuruFocus
Replimune: Stock Buoyant On Third Try At RP1 ApprovalFDA AdCom May Be Crucial (REPL) - Seeking Alpha
Replimune (REPL) Receives Double Upgrade Amid Positive FDA Devel - GuruFocus
BMO Capital Upgrades Replimune to Outperform From Underperform, Adjusts PT to $16 From $1 - marketscreener.com
BMO upgrades Replimune stock rating on FDA filing progress By Investing.com - Investing.com Canada
symbol__ Stock Quote Price and Forecast - CNN
Replimune Group, Inc. Stock 12‑Month Price Target Raised to $8.17, Implies 30% Downside - TradingView
Replimune's Fiscal Q4 Net Loss Narrows - Moomoo
Replimune gets FDA review for melanoma drug after prior setbacks - The Pharma Letter
Replimune Group Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Replimune Group FY 2026: Revenue $0 Net loss $(313.9)M — 10-K Summary - TradingView
Replimune (NASDAQ: REPL) outlines RP1 melanoma data and high-stakes FDA review - Stock Titan
Replimune Group reports FY2026 net loss $313.9M, cash $268.9M, FDA accepts RP1 BLA resubmission - TradingView
Replimune (REPL) widens FY 2026 loss as FDA accepts RP1 melanoma BLA - Stock Titan
Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update - The Manila Times
Replimune’s melanoma drug review moves toward Aug. 2 FDA decision - Stock Titan
Replimune reports fiscal 2026 results and FDA BLA progress for RP1 in melanoma - grafa.com
Replimune Group, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Investors SueWallSt as Replimune Group, Inc. Faces Securities Fraud Allegations - The National Law Review
Replimune Group, Inc. (REPL) Class Action Lawsuit: Levi & Korsins - The National Law Review
REPL SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
REPL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
REPL LAWSUIT ALERT: Levi & Korsinsky Notifies Replimune Group, In - The National Law Review
Levi & Korsinsky Notifies Replimune Group, Inc. (REPL) Shareholde - The National Law Review
Investor Alert: Deadline Approaching to Join Replimune Group, Inc. (REPL) Class ActionContact Levi & Korsinsky - The National Law Review
Replimune upgraded by Analyst with a new price target - Quantisnow
Replimune (REPL) Receives Upgrade from JPMorgan with Increased P - GuruFocus
Replimune (REPL) Shares Decline After FDA Advisory Committee Ann - GuruFocus
Replimune (REPL) Receives FDA Review for Advanced Melanoma Treat - GuruFocus
Replimune Group, Inc. Stock 12‑Month Price Target Raised to $7.67, Implies 31% Downside - TradingView
FDA Accepts Third RP1 BLA Resubmission for Advanced Melanoma - Dermatology Times
Replimune reveals FDA acceptance of resubmitted BLA for RP1 plus nivolumab - grafa.com
FDA accepts Replimune’s resubmitted application for RP1 - Investing.com UK
Replimune Group Inc : JP Morgan Raises to Ove - Moomoo
JPMorgan Upgrades Replimune Group to Overweight From Neutral, $17 Price Target - marketscreener.com
FDA accepts Replimune’s resubmitted application for RP1 By Investing.com - Investing.com Australia
JPMorgan released its latest research report, significantly upgrading the stock rating of biotechnology company Replimune Group Inc. from "Neutral" to "Overweight." - Bitget
Replimune Group Inc. announced that the U.S. Food and Drug Administration (FDA) has officially accepted its resubmitted Biologics License Application (BLA) for the investigational therapy RP1 for the treatment of advanced melanoma. - Bitget
Replimune Group Inc (REPL) 財務データ
収益
当期純利益
現金流量
EPS
Replimune Group Inc (REPL) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Xynos Konstantinos | Chief Medical Officer |
May 18 '26 |
Sale |
5.08 |
14,023 |
71,237 |
235,662 |
| Schwendenman Andrew | Chief Accounting Officer |
May 18 '26 |
Sale |
5.08 |
7,894 |
40,102 |
107,057 |
| Sarchi Christopher | Chief Commercial Officer |
May 18 '26 |
Sale |
5.08 |
8,626 |
43,820 |
192,962 |
| Astley-Sparke Philip | Director |
May 18 '26 |
Sale |
5.08 |
17,657 |
89,698 |
1,412,414 |
| Patel Sushil | Chief Executive Officer |
May 18 '26 |
Sale |
5.08 |
37,324 |
189,606 |
747,492 |
| Hill Emily Luisa | Chief Financial Officer |
May 18 '26 |
Sale |
5.08 |
7,812 |
39,685 |
236,556 |
| Sarchi Christopher | Chief Commercial Officer |
Apr 02 '26 |
Sale |
8.01 |
6,500 |
52,065 |
151,588 |
2.64%
大文字化:
|
ボリューム (24 時間):